Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

Autor: Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hidalgo Lopez JE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim HR; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Zuo Z; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Janania Martinez M; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Stingo F; Department of Statistics, Computer Science, Applications, The University of Florence, Florence, Italy., Lee J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Luthra R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bueso-Ramos CE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jazyk: angličtina
Zdroj: American journal of hematology [Am J Hematol] 2017 Aug; Vol. 92 (8), pp. E168-E171. Date of Electronic Publication: 2017 May 30.
DOI: 10.1002/ajh.24776
Databáze: MEDLINE